Avanir to sell Merck's Januvia in long-term care settings
This article was originally published in Scrip
Executive Summary
Avanir Pharmaceuticals has entered into an exclusive, three-year agreement with Merck & Co to co-promote Merck's type 2 diabetes therapies Januvia (sitagliptin) and the sitagliptin family of products in the long-term care institutional setting in the US.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.